RecruitingNCT05446805

Depression and Driving

The Impact of Depression and Preclinical Alzheimer Disease on Driving Among Older Adults (Depression and Driving)

Sponsor

Ganesh Babulal

Enrollment

150 participants

Start Date

Jun 17, 2021

Study Type

OBSERVATIONAL

Conditions

Depression Drive

Summary

This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).

Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether depression affects driving safety and ability in older adults, using brain imaging and biological markers to understand the connection between mood and driving behavior. **You may be eligible if...** - You are 65 years or older - You currently drive at least once per week - You have a valid driver's license - You are willing to have a blood draw - You are willing to undergo either a lumbar puncture (spinal fluid test) or PET brain scan **You may NOT be eligible if...** - You are under 65 years old - You do not currently drive or no longer drive a vehicle - You are unwilling to provide a blood sample and at least one additional biological test Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGF 18 AV-1451 (Flortaucipir)

A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).

DRUG[11C]-Pittsburgh Compound B ([11C]PiB)

A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.